REPRISE Study Results and Expert Reactions
The REPRISE study was conducted in late-stage ADPKD patients with chronic kidney disease as part of the tolvaptan clinical development program. It enrolled over 1,300 patients from 213 centres across 21 countries, including 6 centres in Canada.